Loading clinical trials...
Loading clinical trials...
Phase III, Multicentre, Randomised, Double-blind, Comparative Study to Assess the Efficacy and Safety of Lanreotide 30 mg Versus Placebo as a Palliative Treatment of Clinical Symptoms Associated With Intestinal Obstruction Due to Peritoneal Carcinomatosis in Inoperable Patients.
The purpose of this study is to determine whether lanreotide 30mg microparticles are effective in the relief of clinical symptoms due to small bowel obstruction in inoperable patients with peritoneal carcinomatosis.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Clinique Universitaire St. LUC
Brussels, Belgium
Institut Jules Bordet
Brussels, Belgium
Clinique Notre-Dame
Hermalle-sous-Huy, Belgium
Centre Hospitalier de Jolimont-Lobbes
La Louvière, Belgium
Hôpital Nord
Amiens, France
Clinique de l'Anjou
Angers, France
Hôtel-Dieu
Angers, France
CH Victor Dupouy
Argenteuil, France
Hôpital Saint André
Bordeaux, France
Hôpital de la Cavale Blanche
Brest, France
Start Date
September 1, 2003
Primary Completion Date
October 1, 2008
Completion Date
October 1, 2008
Last Updated
November 5, 2020
80
ACTUAL participants
Lanreotide (microparticle formulation)
DRUG
Placebo
OTHER
Lead Sponsor
Ipsen
NCT05053971
NCT05058651
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions